GlassScriptPhysician profile
A Lawrence Attia
NPI 1275575466
$13,246.06
in general payments reported to CMS, 2019-2025
27 companies · $2,296 in 2025
The $2,296 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,739 · 2020: $1,330 · 2021: $1,872 · 2022: $2,239 · 2023: $1,669 · 2024: $2,102 · 2025: $2,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,066.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,004.93 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $2,949.67 | 2019-2025 | Skyrizi, Creon, Linzess |
| Qol Medical, LLC | $2,366.87 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $914.30 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $497.56 | 2023-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $475.91 | 2019-2023 | Dificid, Gardasil 9, Pneumovax 23 |
| Novo Nordisk INC | $461.32 | 2019-2025 | |
| Janssen Biotech, INC. | $343.88 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $337.99 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $303.61 | 2021-2024 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $302.92 | 2019-2025 | Farxiga, Breztri |
| Ironwood Pharmaceuticals, INC | $253.01 | 2019-2024 | Linzess |
| Ardelyx, INC. | $168.35 | 2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $146.18 | 2021-2022 | |
| Redhill Biopharma INC. | $142.18 | 2020-2024 | Talicia, Movantik, Aemcolo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $97.60 | 2019 | |
| Idorsia Pharmaceuticals US INC | $81.34 | 2023-2024 | Quviviq |
| Ferring Pharmaceuticals INC. | $59.80 | 2019-2020 | |
| Braintree Laboratories, INC. | $56.77 | 2021-2022 | |
| Lilly USA, LLC | $50.45 | 2025 | Zepbound, Mounjaro |
| Currax Pharmaceuticals LLC | $46.15 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $45.49 | 2024-2025 | Dupixent |
| Sanofi Pasteur INC. | $39.54 | 2019-2023 | |
| Exact Sciences Corporation | $34.66 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $23.48 | 2019 | |
| Gilead Sciences, INC. | $23.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.10 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw A Lawrence Attia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.